Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pre-emption Among Legal Hurdles For Triaminic Proposed Class Action

This article was originally published in The Tan Sheet

Executive Summary

A proposed class action alleging Novartis marketed pediatric cough/cold products that were ineffective and unsafe likely faces an uphill battle, according to industry attorneys including former FDA Chief Counsel Peter Barton Hutt

You may also be interested in...



As FDA Eyes Cough/Cold Changes, Alternative Products Aim For Mainstream

Some manufacturers are anticipating changes in FDA's findings on the safety and efficacy of OTC cough/cold medicines for 2- to 11-year-old children by promoting alternative products such as nasal decongestant sprays and washing devices

As FDA Eyes Cough/Cold Changes, Alternative Products Aim For Mainstream

Some manufacturers are anticipating changes in FDA's findings on the safety and efficacy of OTC cough/cold medicines for 2- to 11-year-old children by promoting alternative products such as nasal decongestant sprays and washing devices

As FDA Eyes Cough/Cold Changes, Alternative Products Aim For Mainstream

Some manufacturers are anticipating changes in FDA's findings on the safety and efficacy of OTC cough/cold medicines for 2- to 11-year-old children by promoting alternative products such as nasal decongestant sprays and washing devices

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel